Why the study?
Patient profiles influence warfarin outcomes, but such data and their implications are scarce in resource-poor countries without access to pharmacogenetics or regular INR testing.
What are the clinical and sociodemographic profiles of adult patients on long-term warfarin therapy in a leading referral hospital in Kenya?
What are the clinical and sociodemographic profiles of adult patients on long-term warfarin therapy in a leading referral hospital in Kenya?
In a Kenyan referral hospital, long-term warfarin therapy is primarily indicated for VTE in obese patients and cardioembolic events in lean, middle-aged males, with an average maintenance dose of 6.17 mg/day.
Highlights warfarin use patterns by indication and demographics in Kenya; leaves open need for prospective studies on optimized dosing in similar settings.
Background: Patients’ profiles affect the outcome with warfarin; however, this data, and its implications, is scarce in resource-poor countries without access to pharmacogenetics or regular INR testing.Objectives: To characterize the profiles of patients on long-term warfarin therapy and subsequently use these to guide future anticoagulation management.Methods: Cross-sectional study among 180 adult patients receiving warfarin therapy in at a leading referral hospital in Kenya. Sociodemographic characteristics were obtained through face-to-face interviews. Details of warfarin therapy, concomitant medication and comorbidities were retrieved from medical records. Associations between patients’ profiles and the clinical indications of anticoagulation were computed at p ≤ 0.05.Results: Warfarin maintenance dose was 6.17 (±2.75) mg per day. Venous thromboembolism (56.6%) amongst obese patients (p = 0.0019) and cardioembolic events (48.3%) among males (p = 0.0316) aged ≤50 years (p = 0.0436) whose body mass indices were ≤ 25 (p < 0.0001) were the most common indications. Two-fifths and 45.0% of the patients had at least one other disease and concomitant medications.Conclusions: Long term warfarin therapy among Kenyans is mainly for overweight or lean middle-aged individuals suffering from venous or cardioembolic diseases. Studies should correlate patients’ profiles with warfarin response to guide future management.
No takes yet. Share an insight, caveat, or question.
Nyamu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: